NeokenBio Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$7.51M
- Investors
-
11
NeokenBio General Information
Description
Developer of drugs intended to treat intractable diseases with efficacy from Hemp. The company develops drugs using NOID and localizes epilepsy drugs that help in the treatment of brain diseases, enabling healthcare companies to provide patients with effective drugs to cure diseases.
Contact Information
Website
www.neocannbio.comCorporate Office
- 506 Global Center
- 117-3, Hoegi-ro
- Seoul, Dongdaemun-gu 02455
- South Korea
Corporate Office
- 506 Global Center
- 117-3, Hoegi-ro
- Seoul, Dongdaemun-gu 02455
- South Korea
NeokenBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 25-Sep-2023 | $7.51M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series A) | 26-Jul-2022 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 31-Oct-2021 | Completed | Generating Revenue | |||
| 1. Seed Round | 30-Sep-2021 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NeokenBio Signals
NeokenBio Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blianx Investment | Venture Capital | Minority | ||
| Medytox Solutions | Corporation | Minority | ||
| Prologue Ventures | Corporate Venture Capital | Minority | ||
| QUAD Investment Management | Hedge Fund | Minority | ||
| BM Ventures | Venture Capital | Minority |
NeokenBio Investments (1)
NeokenBio’s most recent deal was a Joint Venture with Drug Discovery (Kiss of Beauty / NeokenBio). The deal was made on 03-Jun-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Drug Discovery (Kiss of Beauty / NeokenBio) | 03-Jun-2024 | Joint Venture | Drug Discovery |
NeokenBio FAQs
-
When was NeokenBio founded?
NeokenBio was founded in 2021.
-
Where is NeokenBio headquartered?
NeokenBio is headquartered in Seoul, South Korea.
-
What is the size of NeokenBio?
NeokenBio has 16 total employees.
-
What industry is NeokenBio in?
NeokenBio’s primary industry is Drug Discovery.
-
Is NeokenBio a private or public company?
NeokenBio is a Private company.
-
What is NeokenBio’s current revenue?
The current revenue for NeokenBio is .
-
How much funding has NeokenBio raised over time?
NeokenBio has raised $11M.
-
Who are NeokenBio’s investors?
Blianx Investment, Medytox Solutions, Prologue Ventures, QUAD Investment Management, and BM Ventures are 5 of 11 investors who have invested in NeokenBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process